To mark the release of DM for Details: Selling Drugs in the Age of Social Media, Volteface hosted a panelled discussion in Westminster featuring- Mariam, a Youth Ambassador at the Daniel Spargo-Mabbs Foundation; Nick Hickmott, a Young People, Early Intervention and Harm Reduction Worker; Scarlett Furlong, Volteface Policy Advisor and co-author of DM for Details; and as Chair Hardeep Matharu, Editor at Byline Times. Introduced by Liz McCulloch, Director of Policy at Volteface and co-author of DM for Details. 

In this episode Paul talks to Chris Snowdon, Head of Lifestyle Economics at the Institute of Economic Affairs. They have a lively chat discussing their recent trip to Canada with three UK MP's which was covered by the BBC. Chris explains how cannabis nearly made him miss his flights and his impressions of the regulated market.

On this month's edition of the Volteface Podcast, Paul North catches up with cannabis culture veteran & positive thinker Orson Boon. Up for discussion is the effects of psychedelics with the pair considering potential therapeutic benefits of certain psychedelics.

This show was produced by Matt Holborn. If you need help setting up and producing a podcast, get in touch with him at [email protected] or through his website www.northlondonpodcasts.com

This edition of the Volteface podcast is audio recorded from the launch of our most recently released report 'Making the Grade', written in partnership with Mentor. In a change from the regular format, this feature is a panelled discussion focussing on drug education in schools. We hear from an ex-PRU student, a PRU headteacher, CEO of prevention charity Mentor Boris Pomeroy & the mother of an exploited child.

On this month's edition of the Volteface Podcast, host Paul North catches up with Dr. Derek Tracy of the Royal College of Psychiatrists. On the agenda is an in-depth discussion of cannabis & potential links to mental health issues. Key questions covered include: Why can cannabis impact mental health? Why should we talk about cannabis and mental health? Why does talking about it result in such strong reactions from the community? Subscribe and follow us for monthly drug policy related discussion.